Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRA-333 (Lecozotan) in mild to moderate Alzheimer's disease
NCT00151333Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing SRA-333 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of multiple ascending fixed oral doses. Started Feb 2005; status: completed.
02
Drugs
lecozotan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00151333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151333.